SSG
CYTK icon

Summit Securities Group’s Cytokinetics CYTK Stock Holding History

Summit Securities Group’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-17,500
Closed -$823K – 859
2024
Q4 		$823K Sell
17,500
-4,600
-21% -$239K 0.17% 89
2024
Q3 		$1.17M Hold
22,100
– – 0.31% 51
2024
Q2 		$1.2M Sell
22,100
-4,200
-16% -$254K 0.23% 61
2024
Q1 		$1.84M Buy
+26,300
New +$2.03M 0.3% 42

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Summit Securities Group's CYTK Position: Q1 2025 in Review

Summit Securities Group sold out of Cytokinetics (CYTK) in Q1 2025, closing a stake of 17,500 shares — an estimated $823K sold.

Summit Securities Group first reported a position in CYTK in Q1 2024 and held it in 4 quarters. The position peaked at $1.84M in Q1 2024. 355 funds tracked by Wall St. Rank hold CYTK as of Q1 2025.

  • Summit Securities Group reported no remaining Cytokinetics position as of Q1 2025 after selling out during the quarter.
  • Summit Securities Group sold 17,500 Cytokinetics shares in Q1 2025, an estimated $823K.
  • Summit Securities Group first reported a position in Cytokinetics in Q1 2024 and held it in 4 quarters.
  • Summit Securities Group's Cytokinetics position peaked at $1.84M in Q1 2024.
  • 355 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2025.

Based on Summit Securities Group's 13F filing for Q1 2025, filed 13 May 2025.